

1 **Dengue in western Uganda: A prospective cohort of children presenting with**
2 **undifferentiated febrile illness**

3

4

5 Ross M. Boyce^{1,2*}, Matthew Collins³, Rabbison Muhindo², Regina Nakakande², Emily J.
6 Ciccone¹, Samantha Grounds¹, Daniel Espinoza³, Yerun Zhu³, Michael Matte², Moses
7 Ntaroo², Dan Nyehangane^{2,5}, Jonathan J. Juliano¹, and Edgar M. Mulogo²

8 ¹Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill,
9 North Carolina, 27599, USA

10

11 ²Department of Community Health, Faculty of Medicine, Mbarara University of Science &
12 Technology, Mbarara, Uganda

13

14 ³Division of Infectious Diseases, Emory University, Atlanta, Georgia, 30322, USA

15

16 ⁴College of Arts and Sciences, University of North Carolina at Chapel Hill, Chapel Hill,
17 North Carolina, 27599, USA

18

19 ⁵Epicentre Mbarara Research Centre, Mbarara, Uganda

20

21 *Corresponding author:

22

23 Ross M. Boyce MD, MSc
24 Division of Infectious Diseases
25 University of North Carolina at Chapel Hill
26 130 Mason Farm Road
27 Chapel Hill, NC USA 27599
28 Phone: 919.966.2537
29 roboyce@med.unc.edu

30

31 **Keywords:** Dengue, fever, arbovirus, epidemiology, Uganda

32

33 **Running Title:** Dengue in Western Uganda

34

35 **Word Count:** Abstract – 197 | Text – 3,087

36 **ABSTRACT**

37 **Background:** The spatial distribution and burden of dengue in sub-Saharan Africa
38 remains highly uncertain, despite high levels of ecological suitability. The goal of this
39 study was to describe the epidemiology of dengue among a cohort of febrile children
40 presenting to outpatient facilities located in areas of western Uganda with differing levels
41 of urbanicity and malaria transmission intensity.

42

43 **Methods:** Eligible children were first screened for malaria using rapid diagnostic tests.
44 Children with a negative malaria result were tested for dengue using a combination
45 NS1/IgM/IgG rapid test (SD Bioline Dengue Duo). Confirmatory testing by RT-PCR was
46 performed in a subset of participants. Antigen-capture ELISA was performed to estimate
47 seroprevalence.

48

49 **Results:** Only 6 of 1,416 (0.42%) children had a positive dengue rapid test, while none
50 of the RT-PCR results were positive. ELISA testing demonstrated reactive IgG
51 antibodies in 28 (2.2%) participants with the highest prevalence seen at the urban site in
52 Mbarara (19 of 392, 4.9%, $p < 0.001$).

53

54 **Conclusions:** Overall, these findings suggest that dengue, while present, is an
55 uncommon cause of non-malarial, pediatric febrile illness in western Uganda. Further
56 investigation into the ecological factors that sustain low-level transmission in urban
57 settings are urgently needed to reduce the risk of epidemics.

58 **Background**

59 Dengue is a mosquito-borne viral disease that is estimated to cause upwards of 400
60 million infections each year [1, 2]. While more than half of the world's population is
61 thought to be at risk, the global distribution and burden of dengue remains highly
62 uncertain [3]. Nowhere is this epidemiological uncertainty more pronounced than in
63 Africa, where the requisite laboratory infrastructure to distinguish dengue from other
64 causes of febrile illness is not routinely available [4]. Despite limited data, there is
65 reasonable consensus for the existence of endemic dengue transmission in many
66 countries, with modeling frameworks suggesting that Africa's disease burden may be
67 similar to that of other high transmission areas, such as the Americas [1].

68

69 The indirect evidence supporting endemic dengue transmission in Uganda is relatively
70 strong. There are favorable precipitation and temperature conditions, the *Aedes aegypti*
71 mosquito - the primary vector of dengue, along with yellow fever and Rift Valley fever -
72 is ubiquitous in Uganda. Dengue outbreaks and transmission have been documented in
73 neighboring countries, and cases have been reported among travelers returning from
74 Uganda [1, 5, 6]. Other factors favoring the likelihood of dengue transmission in Uganda
75 include an increasingly globalized economy and rapid urbanization [7, 8].

76

77 While the majority of dengue infections result in either asymptomatic or mild, self-limited
78 clinical disease, the potential health system and economic impact of dengue
79 transmission in a malaria-endemic country like Uganda is significant but also not well
80 understood. Given the non-specific symptoms and lack of available diagnostic tools,
81 dengue infections may frequently be misdiagnosed and empirically treated as malaria
82 [6]. This likely contributes to (i) over-estimation of malaria transmission, (ii) over-use of
83 artemisinin combination therapies (ACT), perhaps accelerating to the development of

84 resistance, and (iii) inadequate resourcing of dengue surveillance and control measures,
85 which generally do not overlap with malaria control strategies such as insecticide-treated
86 nets (ITN) [9].

87

88 Defining the burden of dengue in countries like Uganda is critically important, especially
89 as new tools such as vaccines become more widely available [10, 11]. Therefore, the
90 overarching aim of this study was to describe the epidemiology of dengue among a
91 cohort of children presenting to outpatient public health facilities in western Uganda with
92 acute febrile illness.

93

94 **Methods**

95 *Study Setting*

96 The study was conducted at two sites in the Kasese District and one site in the Mbarara
97 District of Southwest Uganda (**Figure 1**). These facilities were purposefully selected to
98 examine dengue as a potential cause of non-malarial febrile illness across different
99 ecological settings and in areas of varying malaria transmission intensity (**Table 1**).
100 There are no government-provided diagnostic tools or standardized treatment protocols
101 for dengue fever at public health facilities in Uganda [12].

102

103 *Study Design*

104 The study was a prospective, observational cohort design, enrolling malaria-negative,
105 febrile children from November 2017 to June 2018. Children (age <18 years) presenting
106 to one of three outpatient clinics with documented fever (axillary temperature ≥ 38.0
107 celsius [C]) or a reported history of fever within the last 7 days were eligible for inclusion.
108 Children presenting without a parent or guardian to provide consent were excluded. After
109 consent was provided, study personnel recorded demographic information, vital signs,

110 and administered a brief health questionnaire.

111

112 Laboratory staff performed a malaria rapid diagnostic test (mRDT) (SD Bioline Malaria
113 Ag P.f, Standard Diagnostics, Republic of Korea) and collected dried blood spots (DBS)
114 on filter paper (Whatman, Chicago, IL). DBS sampling was chosen as a pragmatic but
115 effective option for sampling children across the different field conditions at our study
116 sites [13]. The reliability of measuring antibodies eluted from DBS has been validated
117 several times, [14, 15] and we and others have used DBS-based serology to study the
118 epidemiology of arboviruses in both standard ELISA as well as multiplex platforms [16-
119 18]. Children with a positive mRDT result were excluded from further participation.

120 Children with a negative mRDT result subsequently underwent testing with a dengue
121 rapid diagnostic test (dRDT) (SD Bioline Dengue Duo, Standard Diagnostics Korea).
122 Participants at the Mbarara Regional Referral Hospital outpatient clinic, where a reliable
123 cold chain was available, had 5 mL of venous rather than capillary blood drawn into
124 serum separator tubes for further testing in addition to the dRDT.

125

126 Results of the dRDT were provided to the responsible clinician for the purposes of
127 counseling and case management. Treatment and disposition (i.e. admission versus
128 discharge) plans, as determined by the clinician, were recorded. DBS were stored at
129 room temperature under desiccation and serum samples were stored at -20 °C until
130 analysis.

131

132 *Laboratory Methods*

133 All RDTs for the study were obtained directly from the manufacturer, stored in the
134 original packaging at room temperature, and used in accordance with the manufacturer's
135 instructions prior to the expiration date. Further description of specific procedures is

136 provided below.

137

138 *Elution of dried blood spots for serologic analysis*

139 Plasma proteins were eluted from DBS as previously described [16-18]. One 6-mm hole
140 punch of each DBS was placed in a 1.5 mL Eppendorf tube with 300 μ L of phosphate-
141 buffered saline, and rotated for 2 hour at 37°C. This yielded an eluate that is equivalent
142 to a 1:40 plasma dilution. Eppendorf tubes were centrifuged then eluate transferred to a
143 new tube. Eluate was heat inactivated for 30 minutes in a 56°C water bath. The samples
144 were centrifuged again to pellet proteinaceous debris and the supernatant was
145 transferred to a new tube and stored at 4°C for up to 1 week or at -20°C until use.

146

147 *Antigen capture IgG ELISA*

148 Binding IgG to DENV or ZIKV was measured by antigen capture ELISA as previously
149 described [19]. Briefly, DENV antigen (an equal volume mixture of supernatant from
150 each of the four DENV serotypes cultured in C6/36 cells) was captured by the anti-E
151 protein mouse mAb 4G2 [20]. Plates were blocked with 3% nonfat dry milk, and
152 incubated with DBS eluate at 37°C for 1 hour, and binding was detected with an alkaline
153 phosphatase-conjugated goat anti-human IgG secondary Ab and *p*-nitrophenyl
154 phosphate substrate. Absorbance at 405 nm (optical density, OD) was measured by
155 spectrophotometry on a plate reader. ELISA data are reported as OD values that are the
156 average of technical replicates. The average OD for technical replicates using DBS
157 eluate obtained from flavivirus-naïve individuals (NHS) served as the negative control in
158 ELISA assays. The cut off for positivity was calculated for each plate as the average OD
159 of NHS = standard deviations + 0.1 [16-18].

160

161 *IgM ELISA*

162 Testing for anti-DENV IgM was only performed on participant samples with either a
163 positive dRDT or IgG ELISA per CDC MAC ELISA protocol after titrating individual
164 reagents per instructions [21]. DBS eluate was tested at 1:40 dilution. DENV1-4 antigen
165 was the same as for IgG ELISA above. Plates were washed 3 times between each step.
166 The Enhanced K-Blue TMB substrate reaction was stopped after 30 minutes by addition
167 of 50 μ L 1N HCl. Optical density (OD) of each well was determined within 5 minutes at
168 450nm.

169

170 *Neutralization Assays*

171 Neutralization titers were determined by 96-well microFRNT [22, 23]. Due to limited
172 sample availability from DBS, an abbreviated neutralization assay format was used
173 (eFRNT). DBS eluates were run in singleton over four 4-fold dilutions. Serial dilutions of
174 DBS eluate were mixed with approximately 75-100 focus-forming units of virus in DMEM
175 with 2% FBS. The virus-antibody mixtures were incubated for 1 hour at 37°C and then
176 transferred to a monolayer of Vero cells for infection for 2 hours at 37°C. OptiMEM
177 overlay media supplemented with 2% FBS and 5g (1%) Carboxymethylcellulose was
178 then added, and cultures were incubated for 48 hours (DENV2 and DENV4) or 52 hours
179 (DENV1, DENV3). Cells were fixed with 100 μ L of 1:1 methanol:acetone for 30 minutes.
180 100 μ L of permeabilization buffer was added for 10 minutes followed by 100 μ L of
181 blocking buffer (3% normal goat plasma in permeabilization buffer) and left overnight at
182 4°C. 50 μ L of 4G2 at 12.5 ng/ μ L were added to the plates and incubated for 1 hour at
183 37°C. Cells were washed with a microplate washer followed by the addition of 50 μ L of
184 1:3000 horseradish peroxidase-conjugated goat anti-mouse secondary antibody for 1
185 hour at 37°C. Foci were visualized with 100 μ L of True Blue and counted with a user-
186 supervised automated counting program on 2x-magnified images of micro-wells

187 obtained on a CTL ELISPOT reader. NHS controls were included on every plate to
188 define 100% infection. The eFRNT value is a discrete number corresponding to the
189 dilution factor at which 50% maximum FFU are observed or the average of the two
190 dilution factors between which 50% FFU is crossed.

191

192 *Real-time Polymerase Chain Reaction*

193 Whole blood was drawn into serum separator tubes and centrifuged. Viral RNA was
194 extracted from 140 μ L of serum using the QIAamp extraction kit (QIAGEN Hilden,
195 Germany) and eluted in 60 μ L. Real time PCR was performed on the Rotor-Gene Q
196 (QIAGEN Hilden, Germany) platform using the RealStar [®] kits for Dengue, V2.0,
197 Chikungunya, V2.0 and Zika V.1.0 (Altona Diganostics, Hamburg, Germany) in
198 accordance with manufacturer's instructions.

199

200 *Statistical analysis*

201 Data was collected in a REDCap database and analyzed with Stata 15.1 (College
202 Station, TX) [24]. We summarized participant characteristics and compared them
203 between those with positive and negative mRDT results using Student's t-test (normally
204 distributed data) or Wilcoxon rank-sum test (nonparametric data) for continuous
205 variables and Pearson χ^2 test for categorical variables. In a post-hoc analysis, we
206 performed multivariable regression analyses to explore the demographic, geographic,
207 and clinical parameters associated with the primary outcome of interest: a positive
208 dengue IgG. All variables that were significant in univariate models with a pre-specified
209 p -value of <0.25 were included in the subsequent multivariate analysis [25]. A resulting
210 p -value of <0.05 was considered statistically significant in the final models.

211

212 **Results**

213 A total of 1,702 children met the eligibility criteria and were screened for malaria with a
214 mRDT. Complete laboratory results were available for 1,693 (99.5%) participants, who
215 were subsequently included in the analysis. Characteristics of the cohort are
216 summarized in **Table 2**. The median age was 5 years (IQR 2 – 10), although children at
217 Bugoye were significantly older (10 years, IQR 5 – 14, $p < 0.0001$), likely attributable to an
218 existing village-based, community health worker led fever management intervention
219 targeting children less than five years of age and reducing the number of these patients
220 that presented to our study site [26].

221

222 Overall, 369 children (21.8%) had a positive mRDT result. The lowest rate was observed
223 at MRRH (17 of 455, 3.7%, 95% CI 2.3 – 5.9), whereas much higher rates were seen in
224 Kasese (138 of 606, 22.8%, 95% CI 19.6 – 26.3) and Bugoye (214 of 632, 33.9%, 95%
225 CI 30.3 – 37.7). Self-reported ITN use was associated with a protective effect against
226 malaria (IRR 0.70, 95% CI 0.54 – 0.90, $p = 0.006$), but when excluding the low-
227 transmission site, the effect was no longer significant (IRR 0.85, 95% CI 0.65 – 1.11,
228 $p = 0.25$).

229

230 There was overlap in self-reported symptoms between children with positive and
231 negative mRDT results (**Table 2**). Among all participants, cough (69.1%), headache
232 (63.6%), and rhinorrhea (53.0%) were the most frequently reported symptoms. A total of
233 431 (25.4%) participants reported all three of these symptoms, 364 (84.5%) of whom
234 had a negative mRDT result. Participants with a negative mRDT were also more likely to
235 have sought care and received treatment for malaria within the past 14 days. In contrast,
236 arthralgia and myalgia were more frequently reported in the mRDT positive group.

237

238 Of the 1,324 participants with a negative mRDT test result, 1,285 (97.1%) had an
239 evaluable dRDT result, of which 5 (0.39%) had a positive result, defined as a visible
240 NS1, IgM, or IgG band. Individual tests results include one child with positive IgM bands,
241 three with positive IgG bands, and one with positive IgM and IgG bands. There were
242 three positive dRDT results in Bugoye, two in Mbarara, and and one in Kasese (**Figure**
243 **2**) All samples from MRRH tested by RT-PCR were negative for DENV, CHIKV, and
244 ZIKV.

245

246 Serological testing of 1,247 DBS samples from participants with a negative mRDT test
247 result identified reactive IgG antibodies in 28 (2.3%) participants. There was a significant
248 difference in seroprevalence between Mbarara (19 of 392, 4.9%), which is a more urban
249 center, and the rural sites (Kasese 2 of 453, 0.4%; Bugoye 7 of 414, 1.7%; $p < 0.001$).

250 The Mbarara study site was the only significant predictor of a dengue infection in the
251 multivariable analysis when using Kasese as the reference, although there was a
252 statistical trend towards males being at higher risk of infection ($p = 0.10$) (**Table 3**).

253 Samples that were positive by RDT or IgG ELISA were also tested by eFRNT and DENV
254 IgM-ELISA, but none were positive for IgM antibodies.

255

256 Of the 28 participants with a reactive IgG antibodies by ELISA, only 1 (3.6%) had a
257 positive IgG band on the dRDT. This occurred in the one patient with both IgM and IgG
258 bands positive on the dRDT. Overall, the correlation in IgG results between the dRDT
259 and ELISA was poor ($\kappa = 0.06$, 95% CI 0 – 0.40).

260

261 Among those with a negative mRDT result, 1,297 of 1,324 (98.0%) received treatment
262 with an antibiotic, including five who also received treatment with
263 artemether/lumefantrine (AL). An additional 17 (1.3%) received treatment with AL (and

264 no antibiotic) despite negative mRDT test results. The vast majority of children (1,279 of
265 1,316, 97.2%) were discharged from the outpatient clinics, while 35 (2.7%) were
266 admitted. There were no significant differences in admission rates by sex, age category,
267 or clinical site.

268

269 **Discussion**

270 Despite favorable climate and ecology, our findings suggest that dengue is an
271 uncommon cause of non-malarial, pediatric febrile illness in western Uganda. Our results
272 are consistent with those obtained from a laboratory-based surveillance system of
273 inpatient pediatric admissions across six sentinel sites in Uganda, which reported recent
274 arboviral infection in only 18 of 622 (2.9%) samples tested [27], as well as multi-site
275 seroprevalence study of healthy adult blood donors, which identified dengue antibodies
276 in 72 of 1,744 (4.1%) of donors [28]. However, these data exclude neither the possibility
277 of sporadic dengue outbreaks in the past or future nor the possibility that dengue or
278 other *Aedes*-borne viruses could establish endemicity in this region given the favorable
279 ecological conditions. Our time-limited and geographically-restricted study design,
280 however, does provide a robust snapshot of current arbovirus transmission. While
281 seroprevalence studies that include older subjects may increase the sensitivity for
282 detecting historic dengue transmission, our findings do provide strong evidence for the
283 presence of low-level transmission, particularly at the more urban site in Mbarara. In
284 areas of higher transmission, dengue seroprevalence is typically 20% or greater in
285 young children [29-31]. The few cases detected here, along with the large susceptible
286 population make dengue introduction a major concern, and surveillance together with
287 further investigation of the demographic, spatial, and entomologic factors that could
288 support epidemic and endemic dengue infection in urban East Africa should be a high
289 priority.

290

291 Given the low number of positive cases, a rigorous assessment of the performance of
292 the dengue rapid diagnostic tests was not possible. The relatively poor correlation in IgG
293 results between the dRDT and the ELISA is consistent with a study of febrile outpatients
294 conducted in the Democratic Republic of Congo, which showed 2.5% IgG positivity by
295 dRDT and 34.0% positivity by ELISA with an estimated sensitivity of 7.6% [32]. It is
296 crucial to note that dRDT are designed for use in the setting of acute infection and not
297 for seroprevalence studies. The main advantage of including IgG testing in this context is
298 in secondary infection, when IgG may rise quickly and dramatically, suppressing the IgM
299 response and limiting unbound dengue antigen present in serum [33]. In primary
300 infection, patients would typically present before an IgG response has developed. A
301 recent systematic review evaluated the potential of dRDT to function as a measure of
302 seroprevalence but found performance to be suboptimal, with sensitivity ranging from
303 30-60% [34].

304

305 Our results do highlight the urgent need for better diagnostics and management
306 algorithms for children with acute febrile illness. Malaria was identified as the cause of
307 fever in only 22% of participants, and among participants with a negative malaria test,
308 nearly 80% reported cough or rhinorrhea with more than half (51.1%) reporting both
309 symptoms. While not confirmed by microbiologic or molecular methods, many of these
310 children likely had viral infections that would be self-limited and not require antibiotic
311 treatment [35]. Yet more than 97% of children with a negative malaria test result across
312 all three sites received a course of antibiotic treatment. Given the growing global threat
313 of antimicrobial resistance, driven in part by antimicrobial overuse, this patient population
314 represents an important target for antibiotic stewardship interventions.

315

316 To our knowledge, our study is one of the first to examine the burden of dengue among
317 children presenting to outpatient clinics in western Uganda with undifferentiated febrile
318 illness. Strengths of our approach include the diverse geography of the clinical sites,
319 large sample size, and different diagnostic testing strategies (i.e. dRDT, ELISA, PCR).
320 The study also has a number of limitations. First, we excluded children with a positive m
321 RDT from further consideration. While dengue-malaria coinfections have been reported
322 in other settings [6], this was expected to be a relatively infrequent occurrence. To
323 explore this possibility, however, we tested 131 mRDT positive children at the Kasese
324 site, only one (0.77%) of who had a positive IgM band on the dRDT; a prevalence similar
325 to children with a negative mRDT ($p=0.53$). Second, our facility-based and temporally-
326 limited enrollment strategy may have missed focal outbreaks of dengue in the
327 community. Dengue is well-known to emerge rapidly in non-immune populations then
328 quickly disappear. Studies from neighboring countries and other surveillance methods
329 do, however, support the validity of our findings. Third, IgG ELISA may overestimate
330 dengue prevalence as this assay may also detect cross-reactive antibodies elicited by
331 infection by related flaviviruses, though neutralization testing also supported prior
332 infection by dengue for some subjects in this population [36, 37]. Lastly, we did not have
333 the means to screen all specimens for anti-dengue IgM, which precluded a direct
334 comparison of serologic IgM testing to the dRDT result.

335

336 **Conclusions**

337 Dengue does not account for a large proportion of non-malarial, acute febrile illness
338 presentations in western Uganda. However, the presence of the vector and the
339 pathogen, along with a large susceptible population make sporadic outbreaks a major
340 concern. Further investigation into the ecological factors that sustain low-level
341 transmission in urban centers such as our Mbarara site, are urgently needed.

342 **Abbreviations**

343	ACT	Artemisinin combination therapies
344	AL	Artemether/lumefantrine
345	C _o	Degress celsius
346	CHIKV	Cikungunya Virus
347	DBS	Dried Blood Spot
348	DENV	Dengue Virus
349	dRDT	Dengue rapid diagnostic test
350	ELISA	Enzyme Linked immunosorbent Assay
351	ITN	Insecticide-treated nets
352	mRDT	Malaria rapid diagnostic test
353	MRRH	Mbarara Regional Referral Hospital
354	NS1	Non-structural protein 1
355	OD	Optical Density
356	RNA	Ribonucleic acid
357	RT-PCR	Reverse-Transcriptase Polymerase Chain Reaction
358	ZIKV	Zika Virus

359 **Declarations**

360 *Ethics Approval and Consent to Participate*

361 Ethical approval of the study was provided by the institutional review boards of the
362 University of North Carolina at Chapel Hill, the Mbarara University of Science and
363 Technology, and the Uganda National Council for Science and Technology. Written
364 informed consent for participation in the study was obtained from all adult participants or
365 from their parent or guardian when participants were children (under 18 years old).

366

367 *Competing Interests*

368 All authors have completed the ICMJE uniform disclosure form and declare: no financial
369 relationships with any organisations that might have an interest in the submitted work in
370 the previous three years; no other relationships or activities that could appear to have
371 influenced the submitted work.

372

373 *Consent for Publication*

374 Not applicable.

375

376 *Funding*

377 The study was supported by Takeda Vaccines. Standard Diagnostics provided the rapid
378 diagnostic tests for the study at no cost. RMB is supported by the National Institutes of
379 Health (K23AI141764). JJJ received support from National Institute of Health
380 (K24AI13499). EJC is supported by the National Institutes of Health (5T32HL007106-43).
381 Neither Takeda nor Standard Diagnostics nor had any role in the design or conduct of the
382 study or preparation of the manuscript.

383

384 *Author Contributions*

385 Study conception and design: RMB, MHC, EM. Funding: RMB. Study implementation:
386 RMB, RM, RK, EC MM, MN, DN, EM. Laboratory testing: RK, DN, SG, DE, YZ, MHC. First
387 draft of manuscript: RMB, SG, EC, MHC, DN. Revisions: All.

388

389 *Availability of Data and Materials*

390 Deidentified individual data that supports the results will be shared beginning 9 to 36
391 months following publication provided the investigator who proposes to use the data has
392 approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC),
393 or Research Ethics Board (REB), as applicable, and executes a data use/sharing
394 agreement with UNC.

395

396 *Acknowledgements*

397 We wish to thank the clinical staff and patients of the Bugoye Health Centre, Kasese
398 Health Centre, and Mbarara Regional Referral Hospital Outpatient Department for their
399 participation and support. We also thank Corinna Keeler for the cartography support.

400

REFERENCES

401

- 402 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM,
403 Brownstein JS, Hoen AG, Sankoh O *et al*: **The global distribution and burden of**
404 **dengue**. *Nature* 2013, **496**(7446):504-507.
- 405 2. Simmons CP, Farrar JJ, Nguyen v V, Wills B: **Dengue**. *The New England journal of*
406 *medicine* 2012, **366**(15):1423-1432.
- 407 3. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL,
408 Farlow AW, Scott TW, Hay SI: **Refining the global spatial limits of dengue virus**
409 **transmission by evidence-based consensus**. *PLoS neglected tropical diseases* 2012,
410 **6**(8):e1760.
- 411 4. WHO: **WHO report on global surveillance of epidemic-prone infectious diseases:**
412 **dengue and dengue haemorrhagic fever**. In. Geneva: World Health Organization;
413 2014.
- 414 5. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS: **Dengue virus infection in Africa**.
415 *Emerging infectious diseases* 2011, **17**(8):1349-1354.
- 416 6. Chipwaza B, Mugasa JP, Selemani M, Amuri M, Mosha F, Ngatunga SD, Gwakisa PS:
417 **Dengue and Chikungunya fever among viral diseases in outpatient febrile children**
418 **in Kilosa district hospital, Tanzania**. *PLoS neglected tropical diseases* 2014,
419 **8**(11):e3335.
- 420 7. Jaenisch T, Junghanss T, Wills B, Brady OJ, Eckerle I, Farlow A, Hay SI, McCall PJ,
421 Messina JP, Ofula V *et al*: **Dengue expansion in Africa-not recognized or not**
422 **happening?** *Emerging infectious diseases* 2014, **20**(10).
- 423 8. Statistics UBo: **National Population and Housing Census 2014**. In. Kampala: Republic
424 of Uganda; 2014.
- 425 9. Anders KL, Hay SI: **Lessons from malaria control to help meet the rising challenge**
426 **of dengue**. *The Lancet Infectious diseases* 2012, **12**(12):977-984.
- 427 10. Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P,
428 Sirivichayakul C, Watanaveeradej V, Rivera L, Espinoza F *et al*: **Efficacy of a**
429 **Tetravalent Dengue Vaccine in Healthy Children and Adolescents**. *The New England*
430 *journal of medicine* 2019, **381**(21):2009-2019.
- 431 11. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H,
432 Costa MS, Morales-Ramirez JO, Carrasquilla G *et al*: **Efficacy of a tetravalent dengue**
433 **vaccine in children in Latin America**. *The New England journal of medicine* 2015,
434 **372**(2):113-123.
- 435 12. Uganda Ministry of Health: **National Guidelines for the Management of Common**
436 **Conditions**. In. Kampala, Uganda; 2016.
- 437 13. Lim MD: **Dried Blood Spots for Global Health Diagnostics and Surveillance:**
438 **Opportunities and Challenges**. *The American journal of tropical medicine and hygiene*
439 2018, **99**(2):256-265.

- 440 14. Andersen NJ, Mondal TK, Preissler MT, Freed BM, Stockinger S, Bell E, Druschel C,
441 Louis GM, Lawrence DA: **Detection of immunoglobulin isotypes from dried blood**
442 **spots**. *J Immunol Methods* 2014, **404**:24-32.
- 443 15. Behets F, Kashamuka M, Pappaioanou M, Green TA, Ryder RW, Batter V, George JR,
444 Hannon WH, Quinn TC: **Stability of human immunodeficiency virus type 1**
445 **antibodies in whole blood dried on filter paper and stored under various tropical**
446 **conditions in Kinshasa, Zaire**. *J Clin Microbiol* 1992, **30**(5):1179-1182.
- 447 16. Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM:
448 **Preexisting neutralizing antibody responses distinguish clinically inapparent and**
449 **apparent dengue virus infections in a Sri Lankan pediatric cohort**. *J Infect Dis* 2015,
450 **211**(4):590-599.
- 451 17. Tissera H, Amarasinghe A, De Silva AD, Kariyawasam P, Corbett KS, Katzelnick L, Tam
452 C, Letson GW, Margolis HS, de Silva AM: **Burden of dengue infection and disease in**
453 **a pediatric cohort in urban Sri Lanka**. *The American journal of tropical medicine and*
454 *hygiene* 2014, **91**(1):132-137.
- 455 18. Willcox AC, Collins MH, Jadi R, Keeler C, Parr JB, Mumba D, Kashamuka M, Tshetu A,
456 de Silva AM, Meshnick SR: **Seroepidemiology of Dengue, Zika, and Yellow Fever**
457 **Viruses among Children in the Democratic Republic of the Congo**. *The American*
458 *journal of tropical medicine and hygiene* 2018, **99**(3):756-763.
- 459 19. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ,
460 Diamond MS, Baric RS, Crowe JE, Jr. *et al*: **Identification of human neutralizing**
461 **antibodies that bind to complex epitopes on dengue virions**. *Proc Natl Acad Sci U S*
462 *A* 2012, **109**(19):7439-7444.
- 463 20. Henchal EA, Gentry MK, McCown JM, Brandt WE: **Dengue virus-specific and**
464 **flavivirus group determinants identified with monoclonal antibodies by indirect**
465 **immunofluorescence**. *The American journal of tropical medicine and hygiene* 1982,
466 **31**(4):830-836.
- 467 21. Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT: **Standardization**
468 **of immunoglobulin M capture enzyme-linked immunosorbent assays for routine**
469 **diagnosis of arboviral infections**. *J Clin Microbiol* 2000, **38**(5):1823-1826.
- 470 22. Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, Lazear HM, de Silva
471 AM: **Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from**
472 **Dengue Virus Infection**. *Emerging infectious diseases* 2017, **23**(5):773-781.
- 473 23. Swanstrom JA, Plante JA, Plante KS, Young EF, McGowan E, Gallichotte EN, Widman
474 DG, Heise MT, de Silva AM, Baric RS: **Dengue Virus Envelope Dimer Epitope**
475 **Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika**
476 **Virus**. *mBio* 2016, **7**(4).
- 477 24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: **Research electronic**
478 **data capture (REDCap)--a metadata-driven methodology and workflow process for**
479 **providing translational research informatics support**. *J Biomed Inform* 2009,
480 **42**(2):377-381.
- 481 25. Hosmer D, Lemeshow, S: **Applied Logistic Regression**. New York: Wiley; 2000.

- 482 26. English L, Miller JS, Mbusa R, Matte M, Kenney J, Bwambale S, Ntaro M, Patel P,
483 Mulogo E, Stone GS: **Monitoring iCCM referral systems: Bugoye Integrated**
484 **Community Case Management Initiative (BIMI) in Uganda.** *Malaria journal* 2016,
485 **15**:247.
- 486 27. Lamorde M, Mpimbaza A, Walwema R, Kamyia M, Kapisi J, Kajumbula H, Sserwanga A,
487 Namuganga JF, Kusemererwa A, Tasimwa H *et al*: **A Cross-Cutting Approach to**
488 **Surveillance and Laboratory Capacity as a Platform to Improve Health Security in**
489 **Uganda.** *Health Secur* 2018, **16**(S1):S76-S86.
- 490 28. Clements TL, Rossi CA, Irish AK, Kibuuka H, Eller LA, Robb ML, Kataaha P, Michael NL,
491 Hensley LE, Schoepp RJ: **Chikungunya and O'nyong-nyong Viruses in Uganda:**
492 **Implications for Diagnostics.** *Open Forum Infect Dis* 2019, **6**(3):ofz001.
- 493 29. L'Azou M, Assoukpa J, Fanouillere K, Plennevaux E, Bonaparte M, Bouckennooghe A,
494 Frago C, Noriega F, Zambrano B, Ochiai RL *et al*: **Dengue seroprevalence: data from**
495 **the clinical development of a tetravalent dengue vaccine in 14 countries (2005-**
496 **2014).** *Trans R Soc Trop Med Hyg* 2018, **112**(4):158-168.
- 497 30. Reller ME, de Silva AM, Miles JJ, Jadi RS, Broadwater A, Walker K, Woods C, Mayorga
498 O, Matute A: **Unsuspected Dengue as a Cause of Acute Febrile Illness in Children**
499 **and Adults in Western Nicaragua.** *PLoS neglected tropical diseases* 2016,
500 **10**(10):e0005026.
- 501 31. Rojas DP, Barrera-Fuentes GA, Pavia-Ruz N, Salgado-Rodriguez M, Che-Mendoza A,
502 Manrique-Saide P, Vazquez-Prokopec GM, Halloran ME, Longini IM, Gomez-Dantes H:
503 **Epidemiology of dengue and other arboviruses in a cohort of school children and**
504 **their families in Yucatan, Mexico: Baseline and first year follow-up.** *PLoS neglected*
505 *tropical diseases* 2018, **12**(11):e0006847.
- 506 32. Proesmans S, Katshongo F, Milambu J, Fungula B, Muhindo Mavoko H, Ahuka-Mundeke
507 S, Inocencio da Luz R, Van Esbroeck M, Arien KK, Cnops L *et al*: **Dengue and**
508 **chikungunya among outpatients with acute undifferentiated fever in Kinshasa,**
509 **Democratic Republic of Congo: A cross-sectional study.** *PLoS neglected tropical*
510 *diseases* 2019, **13**(9):e0007047.
- 511 33. Peeling RW, Artsob H, Pelegrino JL, Buchy P, Cardoso MJ, Devi S, Enria DA, Farrar J,
512 Gubler DJ, Guzman MG *et al*: **Evaluation of diagnostic tests: dengue.** *Nat Rev*
513 *Microbiol* 2010, **8**(12 Suppl):S30-38.
- 514 34. Luo R, Fongwen N, Kelly-Cirino C, Harris E, Wilder-Smith A, Peeling RW: **Rapid**
515 **diagnostic tests for determining dengue serostatus: a systematic review and key**
516 **informant interviews.** *Clin Microbiol Infect* 2019, **25**(6):659-666.
- 517 35. D'Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama-Marro J, Lengeler
518 C, Cherpillod P, Kaiser L, Genton B: **Beyond malaria--causes of fever in outpatient**
519 **Tanzanian children.** *The New England journal of medicine* 2014, **370**(9):809-817.
- 520 36. Allwin R, Doerr HW, Emmerich P, Schmitz H, Preiser W: **Cross-reactivity in flavivirus**
521 **serology: new implications of an old finding?** *Med Microbiol Immunol* 2002,
522 **190**(4):199-202.
- 523 37. Speer SD, Pierson TC: **VIROLOGY. Diagnostics for Zika virus on the horizon.**
524 *Science* 2016, **353**(6301):750-751.
525

Table 1: Description of clinical sites

Study Site	Location	District	GPS	Elevation	Setting	Facility Type	Referral Base	Monthly Clinic Visits	Malaria Prevalence*
Bugoye Health Centre III	Bugoye Village	Kasese	0° 30' N 30° 1' E	1,242m	Rural	Public Health Centre III	50,000	800	17.6%
Kasese Health Centre III	Kasese Town	Kasese	0° 17' N 30° 7' E	980m	Semi-Urban	Public Health Center III	400,000	1,200	17.6%
Mbarara Regional Referral Hospital	Mbarara Town	Mbarara	0° 36' S 30° 4' E	1,442m	Urban	Public Teaching Hospital	2.5 million	1,600	5.7%

*Regional estimates from 2014-15 Uganda Malaria Indicator Survey

Table 2: Demographic and clinical characteristics of the study cohort

Characteristic	All	Malaria RDT Positive	Malaria RDT Negative	p-Value
Patients (n, %)	1,693 (100)	369 (21.8)	1,324 (78.2)	-
Age, (median, IQR)	5 (2 – 10)	7 (4 – 11)	4 (2 – 9)	<0.001*
< 5 years	788 (46.5)	122 (33.1)	666 (50.3)	
5 – 12 years	577 (34.1)	155 (42.0)	422 (31.9)	<0.001
≥ 12 years	328 (19.4)	92 (24.9)	236 (17.8)	
Female sex (n, %)	904 (53.4)	200 (54.2)	704 (53.2)	0.73
Recruitment Site (n, %)				
Bugoye	632 (37.3)	214 (58.0)	418 (31.6)	
Kasese	606 (35.8)	138 (37.4)	468 (35.4)	<0.001
Mbarara	455 (26.9)	17 (4.6)	438 (33.1)	
Slept under bednet (n, %)	1,222 (73.0)	244 (67.2)	978 (74.5)	0.005
Excluding Mbarara	858 (70.3)	235 (67.9)	623 (71.3)	0.25
Days since fever onset (median, IQR)*	3 (2 – 3)	3 (2 – 3)	3 (2 – 3)	0.0008*
Reported Symptoms				
Anorexia/Poor Feeding	234 (13.8)	56 (15.2)	178 (13.4)	0.39
Arthralgia	170 (10.0)	64 (17.3)	106 (8.0)	<0.001
Cough	1,178 (69.1)	208 (56.1)	970 (72.7)	<0.001
Diarrhea	234 (13.8)	34 (9.2)	200 (15.1)	0.004
Headache	1,076 (63.6)	276 (74.8)	800 (60.4)	<0.001
Myalgia	143 (8.5)	59 (16.0)	84 (6.3)	<0.001
Rash	92 (5.4%)	15 (4.1)	77 (5.8)	0.19
Rhinorrhea	897 (53.0)	134 (36.3)	763 (57.6)	<0.001
Seizures	6 (0.4)	1 (0.3)	5 (0.4)	0.76
Vomiting	248 (14.7)	46 (12.5)	202 (15.3)	0.18
Abnormal Vital Signs (n, %)				
Febrile (T ≥38 _o C)	281 (16.6)	75 (20.3)	206 (15.6)	0.03
Hypoxia (SpO ₂ <90%)	93 (5.5)	12 (3.3)	81 (6.2)	0.03
Previously seen at health center for same condition?	252 (15.0)	30 (8.2)	222 (16.8)	<0.001
Taken antimalarials in the last two weeks?	175 (10.4)	26 (7.1)	149 (11.3)	0.02

Abbreviations: RDT = rapid diagnostic test; IQR = interquartile range; C_o = degrees celsius; SpO₂ = oxygen saturation as measured by pulse oximeter. *Determined using Wilcoxon Rank Sum

Table 3: Regression modeling of variables associated with presence of dengue IgG

Variable	Unadjusted			Adjusted*		
	OR	95% CI	p-value	aOR	95% CI	p-value
Male sex	2.08	0.95 - 4.54	0.07	1.93	0.88 – 4.25	0.10
Age category						
< 5 years		REF				
5 – 12 years	1.42	0.62 – 3.25	0.41			
≥ 12 years	1.10	0.39 – 3.16	0.86			
Study site						
Kasese		REF			REF	
Bugoye	3.88	0.80 – 18.8	0.09	4.08	0.84 – 19.8	0.08
Mbarara	11.5	2.66 – 49.6	0.001	11.2	2.59 – 48.5	0.001
Bednet use	1.61	0.61 – 4.27	0.34			

* Variables that were significant in univariate models with a pre-specified P-value of <0.25 were included in the subsequent multivariate analysis

FIGURE LEGENDS

Figure 1: Map showing location of study sites and population density of each location.

Figure 2: Summary of study participation and test results stratified by study site.



